CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Apr. 01, 2023	Apr. 02, 2022	Apr. 03, 2021
Cash Flows from Operating Activities:
Net income	$ 115,401	$ 43,375	$ 79,469
Non-cash items:
Depreciation and amortization	93,307	97,747	84,287
Impairment of assets	607	7,953	21,969
Share-based compensation expense	25,583	24,359	25,516
Gains on divestitures and sale of assets	382	9,603	32,812
Contingent consideration	(504)	10,461	0
Deferred tax benefit	4,783	5,013	(19,866)
Amortization of deferred financing costs	1,970	3,404	564
Provision (benefit) for losses on inventory	664	(861)	7,860
Other non-cash operating activities	6,126	5,592	1,500
Change in operating assets and liabilities:
Change in accounts receivable	(24,421)	(34,974)	44,121
Change in inventories	30,754	24,307	(38,909)
Change in prepaid income taxes	1,688	2,870	(3,822)
Change in other assets and other liabilities	(22,334)	(15,022)	(4,650)
Change in accounts payable and accrued expenses	39,816	7,642	(56,422)
Net cash provided by operating activities	273,058	172,263	108,805
Cash Flows from Investing Activities:
Capital expenditures	(110,191)	(96,509)	(37,040)
Proceeds from divestitures	850	10,642	44,587
Proceeds from sale of property, plant and equipment	1,608	2,022	1,815
Payments to Acquire Businesses, Net of Cash Acquired	2,850	2,500	434,804
Payments to Acquire Other Investments	(33,205)	0	0
Net cash used in investing activities	(143,788)	(86,345)	(425,442)
Cash Flows from Financing Activities:
Term loan borrowings	280,000	0	0
Term loan redemption	(280,000)	0	0
Repayment of term loan borrowings	(9,625)	(17,500)	(21,875)
Proceeds from revolving facility	50,000	0	0
Payments on revolving facility	(50,000)	0	0
Debt issuance costs	(1,118)	0	(13,457)
Net decrease in short-term loans	0	0	(60,000)
Proceeds from issuance of convertible notes	0	0	500,000
Purchase of capped call related to convertible notes	0	0	(47,400)
Contingent consideration payments	(21,593)	(4,791)	0
Proceeds from employee stock purchase plan	4,378	4,209	4,013
Proceeds from exercise of stock options	2,638	2,338	6,217
Share repurchases	(75,000)	0	0
Other financing activities	(44)	(5)	(46)
Net cash (used in) provided by financing activities	(100,364)	(15,749)	367,452
Effect of exchange rates on cash and cash equivalents	(3,936)	(2,978)	4,179
Net Change in Cash and Cash Equivalents	24,970	67,191	54,994
Cash and Cash Equivalents at Beginning of Year	259,496	192,305	137,311
Cash and Cash Equivalents at End of Year	284,466	259,496	192,305
Supplemental Disclosures of Cash Flow Information:
Interest paid	13,587	6,187	7,824
Income taxes paid	17,967	24,298	12,487
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 81,136	$ 51,800	$ 9,287